Zynerba Pharmaceuticals — Corporate Update (August 2019)
32 slides from Zynerba Pharmaceuticals's corporate update, Aug 6, 2019
Slide 1: Forward-Looking Statements
Forward-Looking Statements 2 © 2019 Zynerba Pharmaceuticals, Inc. All rights reserved. Zynerba and Zygel are trademarks of Zynerba Pharmaceuticals, Inc. All other trademarks and registered trademarks are property of their respective owners. trademarks are property of their respective owners. THE STA
Slide 2: Zynerba Pharmaceuticals: A Rare/Near-Rare Neuropsychiatric Company
Zynerba Pharmaceuticals (NASDAQ: ZYNE) 3 A Rare/Near-Rare Neuropsychiatric Company Deep pipeline focused on high unmet medical needs; translating into multi-billion dollar market opportunity with Zygel™ Four clinical shots on goal: FXS, DEE, ASD, 22q Experienced team Proven development and commercia
Slide 3: Deep Clinical Pipeline
Deep Clinical Pipeline 4 *Orphan Drug Designation Zygel Cannabidiol Gel 2019/2020 Milestones Top line pivotal CONNECT-FX data: 1H2020 File FXS NDA: 2H2020 Additional long term FAB-C data Initiate Phase 2 open label study: 1H2019 Top line BRIGHT data: 1H2020 Initiate Phase 2 open label study: 2Q2019
Slide 4: Zygel (ZYN002) Cannabidiol (CBD) Gel
Neuropsych Indications Differentiated Formulation delivers CBD through the epidermis and into the circulatory system Zygel (ZYN002) Cannabidiol (CBD) Gel 5 Unique MOA First & only patent-protected, permeation-enhanced, pharmaceutically- produced CBD gel Transdermal CBD modulates multiple receptors a
Slide 5: Zygel (ZYN002) Cannabidiol (CBD) Gel
Zygel (ZYN002) Cannabidiol (CBD) Gel Neuropsych Differentiated Transdermal Unique MOA a Indications CED First & only patent- Formulation CBD modulates Potential utility in rare / protected, permeation- delivers CBD multiple receptors and near-rare enhanced, through the mediates numerous neuropsychia
Slide 6: Fragile X Syndrome (FXS) Overview
Fragile X Syndrome (FXS) Overview 7 Rare genetic developmental disability Leading known cause of both inherited intellectual disability and autism spectrum disorder Symptoms linked to deficiencies in the endocannabinoid (EC) system System of neurotransmitters regulating emotional responses, behavior
Slide 7: Recent Development Progress in FXS
Recent Development Progress in FXS 8 Received FDA Fast Track designation for treatment of behavioral symptoms associated with FXS Recently issued US patent directed to methods of treating FXS with cannabidiol extends IP protection to 2038 Presented 12-month FAB-C open label Phase 2 data at American
Slide 8: FAB-C Open Label Phase 2 Trial Design
Day 1 to Week 6 Week 7 to 12 Up to 24 months FAB-C Open Label Phase 2 Trial Design 9 Treatment of Fragile X Syndrome Anxiety and Behavioral Challenges with CBD Titration Maintenance Screening Open label extension Dosing initiated at 50 mg Zygel daily; may be titrated up to 250 mg Zygel daily Doses o
Slide 9: FAB-C Open Label Phase 2: Month Three Results
FAB-C Open Label Phase 2 10 Baseline: 18.2 Baseline: 14.5 Baseline: 8.7 Baseline: 5.1 Baseline: 7.9 Baseline: 6.1 41.8% 52.9% 54.9% 32.4% 59.5% 42.6% P=0.0005 P=0.0096 P=0.0034 P=0.0018 P=0.0006 P=0.0237 Mean % Improvement from Baseline Month Three: ABC-CFXS Mean Score Percent Improvement in Behavio
Slide 10: FAB-C Month Three: Percent Improvement vs. 3rd Party Data
FAB-C ABC-CFXS Subscales 11 Month Three: Percent Improvement vs. 3rd Party Data* Socially Unresponsive / Lethargic Does not pay attention Inappropriate Speech Repeats words / phrases Stereotypy Repetitive movements Hyperactivity Disrupts group activities Social Avoidance Seeks isolation Irritability
Slide 11: FAB-C Open Label Phase 2: Month 3 and 12 Results
FAB-C Open Label Phase 2 12 Month 3 and 12: ABC-CFXS Mean Score 57.9* 51.1* 65.7* 36.7* 60.8* 56.5* *P 0.05 Percent Improvement in Behavioral Symptoms of FXS Mean % Improvement from Baseline 77.2* 59.2* 72.2* 40.4* 64.9* 56.5* Patients Completing 12 Months Data from American Psychiatric Association
Slide 12: Zygel Safety Summary Through 12 Months
FAB-C Open Label Phase 2 13 Well tolerated, consistent with previously reported data; no SAEs No clinically meaningful trends in vital signs, ECG, or clinical safety labs including LFTs; no THC detected in plasma Discontinuations Two siblings discontinued in Period 1 One for worsening of pre-existin
Slide 13: CONNECT-FX: A Pivotal Trial In FXS
CONNECT-FX: A Pivotal Trial In FXS 14 Clinical study Of CaNNabidiol (CBD) in ChildrEn and AdolesCenTs with Fragile X (CONNECT-FX) Zygel 250 mg daily 500 mg daily (weight-based dose) Placebo Mirrors Zygel administration Patients randomized (1:1) to receive either Zygel or placebo Treatment Target: 20
Slide 14: CONNECT-FX: Endpoints
CONNECT-FX: A Pivotal Trial In FXS 15 Primary endpoint: Change from baseline to end of treatment in ABC-CFXS Social Avoidance subscale Key secondary endpoints: Change from baseline to end of the treatment in ABC-CFXS Irritability subscale score ABC-CFXS Socially Unresponsive/Lethargic subscale score
Slide 15: CONNECT-FX: Planned FDA Meeting
CONNECT-FX 16 With positive results, Zynerba intends to request a meeting with the FDA to: Determine acceptability of data as basis for NDA filing Seek advice on marketing authorization preparation Zynerba believes indication may include the treatment of behavioral symptoms associated with FXS Evalu
Slide 16: DEE: Developmental and Epileptic Encephalopathies
DEE Developmental and Epileptic Encephalopathies 17
Slide 17: DEE Overview
DEE Overview 18 Doose Syndrome Dravet Syndrome Early Myoclonic Encephalopathy Juvenile Myoclonic Epilepsy (JME) Landau-Kleffner Syndrome Lennox-Gastaut Syndrome (LGS) Ohtahara Syndrome West Syndrome / Infantile Spasms Heterogeneous group of rare / ultra rare epilepsy syndromes Severe cognitive impai
Slide 18: Developing Zygel in DEE
Developing Zygel in DEE 19 Enrollment Complete in BELIEVE 1 Trial Compelling rationale for utility of CBD in DEE Third party clinical data show impact of CBD on seizures and behavioral issues in children Patient enrollment in BELIEVE 1 Phase 2 study complete Six month multi-dose study in DEE patient
Slide 19: BELIEVE 1 Phase 2 Trial in DEE
BELIEVE 1 Phase 2 Trial in DEE 20 Open LaBel Study to Assess the Safety and Efficacy of ZYN002 Administered as a TransdermaL Gel to ChIldren and AdolEscents with DeVelopmental and Epileptic Encephalopathy 48 patients enrolled Three through 17 years of age Screening Maintenance 22 Weeks Titration 4 W
Slide 20: Autism Spectrum Disorder (ASD) in pediatric patients
21 Autism Spectrum Disorder (ASD) in pediatric patients
Slide 21: ASD in Pediatrics Overview
ASD in Pediatrics Overview 22 Near-rare disorder affecting <1MM pediatric and adolescent pts DSM-5 diagnosis Includes Autistic disorder, Asperger’s syndrome, and Pervasive Development Disorder-not otherwise specified (PDD-NOS) Symptoms include Anxiety Restricted, repetitive patterns of behavior Impa
Slide 22: Developing Zygel in ASD
Developing Zygel in ASD 23 Newer studies suggest ASD is linked to disruption in the EC system Altered anandamide signaling may contribute to ASD-related social and communication impairments EC system modulates many cellular functions and molecular pathways altered in ASD: imbalanced GABAergic, gluta
Slide 23: BRIGHT Phase 2 Trial in ASD
BRIGHT Phase 2 Trial in ASD 24 Open-LaBel ToleRabIlity and Efficacy Study of ZYN002 Administered as a Transdermal Gel to CHildren and AdolescenTs with Autism Spectrum Disorder Target: 36 patients Four through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: ONGOING 250 mg to 5
Slide 24: 22q11.2 Deletion Syndrome (22q)
22q11.2 Deletion Syndrome (22q) 25
Slide 25: 22q Overview
22q Overview 26 Most common contiguous gene deletion syndrome Rare disorder: ~81K patients in US Midline condition with abnormalities affecting palate, face, heart and other organs; surgically corrected in infancy Neuropsychiatric illnesses (anxiety disorders, ASD) and learning disabilities common a
Slide 26: 22q Patient Management
22q Patient Management 27 Two primary stages of 22q patient management: During infancy, doctors address acute physical concerns, such as anomalies of heart and palate, with surgery Once the physical concerns are stabilized, focus shifts to managing neuropsychiatric symptoms, such as anxiety and auti
Slide 27: Developing Zygel in 22q
Developing Zygel in 22q 28 CBD may treat neuropsychiatric symptoms in 22q due to activity as: Agonist at serotonin 1A receptors Antagonist at GPR55 receptors Modulator of endocannabinoid system Early control of anxiety may delay the development of psychosis Phase 2 study underway in pediatric and ad
Slide 28: INSPIRE Phase 2 Trial in 22q
INSPIRE Phase 2 Trial in 22q 29 Target: 20 patients Six through 17 years of age Screening Zygel 14 Weeks Weight based dosing: 14 Weeks: ONGOING 250 mg to 500 mg daily Enrollment ongoing Follow up assessments Week 16 / 17 Efficacy assessments (week 14 vs baseline) include: Aberrant Behavior Checklist
Slide 29: Financial Strength
Financial Strength 30 Clean balance sheet No debt, 23.2M shares outstanding (as of August 6, 2019) Cash and cash equivalent position of $88.7M as of June 30, 2019 Includes net proceeds of $27.0M from 2.1M shares sold and issued at a weighted average selling price of $13.50 per share during the secon
Slide 30: Expected Milestones into 2020
Expected Milestones into 2020 31 FXS DEE Other indications 1Q 2Q 3Q 4Q 2019 Present/publish additional data from Phase 2 FAB-C study Report pivotal CONNECT-FX topline results ASD Initiate Phase 2 BRIGHT study 22q Initiate Ph2 INSPIRE study BELIEVE 1 Phase 2 data 1Q 2Q 2020 Report Phase 2 BRIGHT topl
Slide 31: Corporate Overview August 2019
Corporate Overview August 2019
Slide 32: Zynerba Pharmaceuticals Corporate Overview August 2019
—_— Zynerba PHARMACEUTICALS Advancing Science | Improving Connections Corporate Overview August 2019
Zynerba Pharmaceuticals — Corporate Update (August 2019) on 6ix